Sam Chun Dang Pharm
Samchundang Pharm Co Ltd is a South Korean pharmaceutical manufacturing company specializing in ophthalmic drugs and biosimilars. The company manufactures prescription eye drops, glaucoma treatments, anti-inflammatory formulations, generic pharmaceuticals, and advances biosimilar candidates like SCD-411 (aflibercept). Main revenue drivers comprise domestic and export commercial sales of ophthalmic therapeutics, generic prescription medicines, and biosimilar licensing milestone revenues. Samchundang Pharm serves ophthalmologists, hospital networks, prescription pharmacies, and eye care patients across South Korea, Europe, North America, and Asia. The company holds a market-leading position in South Korea for ophthalmic pharmaceutical manufacturing and eye care treatments. Headquartered in Seoul, South Korea, it is listed on the KOSDAQ market.
3 of the funds FundTelligence covers report a position in Sam Chun Dang Pharm.
- Legal name
- Sam Chun Dang Pharm Co Ltd
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 3
Funds holding Sam Chun Dang Pharm
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)